Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: A single-center experience

Bone Marrow Transplantation

Volumn 22, Issue 9, 1998, Pages 899-904

  Manteiga, R ^a   Martino, R ^a   Sureda, A ^a   Labeaga, R ^a   Brunet, S ^a   Sierra, J ^a   Rabella, N ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Antigenemia; BMT; CMV infection

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; VIRUS ANTIGEN;

ADULT; ARTICLE; CLINICAL PROTOCOL; COLITIS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; VIREMIA; VIRUS CULTURE;

EID: 0031739816     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701439     Document Type: Article

References (22)

1. Boeckh M, Myerson D, Bowden RA. Early detection and treatment of cytomegalovirus infections in marrow transplant: methodological aspects and implications for therapeutic interventions. Bone Marrow Transplant 1994: 14: S66-S70.
2. Prentice HG, Kho P. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic hone marrow transplant. Bone Marrow Transplant 1997: 19: 135-142.
3. Van der Bij W, Torensma R, van Son WJ et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 1988; 25: 179-185.
4. Hebart H, Müller C, Löffler J et al. Monitoring of CMV infection: a comparison of PCR from whole blood. piasma-PCR. pp65-antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transplant 1996; 17: 861-868.
5. Rabella N, Perez JL, Pumarola T. El laboratorio de virología en la infección por citomegalovirus. Posibilidades actuates. Enferm Infecc Microbiol Clin 1997; 15: 69-76.
6. Rabella N, Drew L. Comparison of conventional and Shell vial cultures for detecting cytomegalovirus infection. J Clin Microbiol 1990; 28: 806-807.
7. Bacigalupo A, Tedone E, Isaza A et al. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality. Bone Marrow Transplant 1995; 16: 155-161.
8. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991: 325: 1601-1607.
9. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. New Engl J Med 1991; 324: 1005-1011.
10. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-1071.
11. Nicholson VA, Whimhey E, Champlin R et al. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis. Bone Marrow Transplant 1997; 19: 37-41.
12. Takenaka K, Gondo H, Tanimoto K et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associaled disease after allogeneic bone marrow transplantation from unrelated donors. Bone Marrow Transplant 1997; 19: 241-248.
13. Zaia JA, Gallez-Hawkins GM, Tegtmeier BR et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997; 176: 782-785.
14. Krause H, Heban H, Jahn G et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19: 1111-1116.
15. Einsele H, Hebart H, Kauffman C et al. Late onset CMV disease after allogeneic stem cell transplantation. Bone Marrow Transplant 1997; 19 (Suppl. 1): S85.
16. Link H, Arseniev L, Ljungman P et al. Cytomegalovirus infections after allogeneic peripheral blood progenitor cell transplantation - a survey of the infectious diseases working party of EBMT. Blood 1997; 90 (Suppl. 1): 544a.
17. Vlieger AM, Boland GJ, Jiwa NM et al. Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Bone Marrow Transplant 1992; 9: 247-253.
18. Gondo H, Minematsu T, Harada M et al. Cytomegalovirus (CMV) antigenemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 1994; 86: 130-137.
19. Couriel D, Canosa J, Engler H et al. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematologlcal malignancies. Bone Marrow Transplant 1996; 18: 347-353.
20. Koehler M, St George K, Ehrlich GD et al. Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy. J Pediat Hematol/Oncol 1997; 19; 43-47.
21. Boeckh M, Gallez-Hawkins GM, Myerson D et al. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes. pp65 antigenemia, and viral culture. Transplantation 1997; 64: 108-113.
22. Kanda Y, Chiba S, Suzuki T et al. Time course analysis of semi-quantitative PCR and antigenaemia assay for prevention of cytomegalovirus disease after bone marrow transplantation. Br J Haematol 1998; 100: 222-225.